Physician profile
Joel Alderson
NPI 1629121686
$15,796.44
in general payments reported to CMS, 2019-2025
6 companies · $8,850 in 2025
The $8,850 reported for 2025 was more than what 95% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,921 · 2023: $1,275 · 2024: $1,750 · 2025: $8,850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,843 · Honoraria: $1,275 · Travel and Lodging: $1,273 · Food and Beverage: $485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,842.50 |
| Honoraria | $1,275.00 |
| Travel and Lodging | $1,272.90 |
| Food and Beverage | $484.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $7,694.57 | 2025 | |
| Astellas Pharma US INC | $3,921.25 | 2022 | |
| Abbvie INC. | $1,500.00 | 2024 | |
| Agios Pharmaceuticals, INC. | $1,275.00 | 2023 | Pyrukynd |
| E.R. Squibb & Sons, L.L.C. | $1,037.50 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $368.12 | 2024-2025 | Enhertu, Tagrisso |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Alderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.